There is also evidence that MS-H is one of these important molecular markers which not only associated with resistance to 5-fluorouracil (5-FU) based chemotherapy particularly in stage II patients but also predicts the response of CRC to PD-1 blockade [10, 29–31]. Here, PDCD1 is linked to colorectal carcinoma.